Protein Modification Reagents
Avanti Polar Lipids ALC-0159, PEGylated lipid, 500 mg
ALC-0159 is a PEGylated lipid designed to enhance the stability and biocompatibility of lipid nanoparticle (LNP) drug delivery systems. It significantly improves circulation time and bioavailability for therapeutics by reducing immune recognition, making it a key component in mRNA-based vaccines and other drug delivery applications.
- Enhanced stability and biocompatibility for LNP drug delivery
- Facilitates effective nanoparticle encapsulation and intracellular delivery
- Reduces immune recognition and improves bioavailability
- Essential for mRNA-based vaccines, including COVID-19 formulations
- Applicable in nucleic acid delivery, CRISPR, siRNA, and antisense oligonucleotides
- Soluble in ethanol, DMSO, and specific solvent combinations
- Stored at -20°C and shipped on dry ice
- High purity of over 99% (TLC)
Medchemexpress LLC Pomalidomide-5'-PEG8-C2-COOH | 2138440-78-3 | 98.2% | 697.73 g/mol | C32H47N3O14 | 25 MG
Pomalidomide-5'-PEG8-C2-COOH is an E3 ligase ligand-linker conjugate designed as a building block for PROTAC synthesis. It combines a pomalidomide CRBN-binding moiety with an 8-unit PEG linker and a C2 carboxylic acid handle to enable conjugation to target ligands.
- useful building block for proteolysis-targeting chimeras (PROTACs).
- high purity suitable for synthetic applications.
- soluble in DMSO at approximately 100 mg/mL.
- molecular weight about 697.73 g/mol and formula C32H47N3O14.
- storage: pure form -20°C (3 years) or 4°C (2 years).
Medchemexpress LLC Mal-amido-PEG8-TFP ester | 1924596-31-5 | >98% | C32H44F4N2O13 | 1 G
Mal-amido-PEG8-TFP ester is a PEG-based PROTAC linker. It is used in the synthesis of PROTACs, which facilitate the selective degradation of target proteins through the intracellular ubiquitin-proteasome system.
- PEG-based PROTAC linker
- Used in the synthesis of PROTACs
- Exploits the intracellular ubiquitin-proteasome system
- Selectively degrades target proteins
- For research use only
eMolecules 850090-13-0 | Tos-PEG3-t-butyl ester | Broadpharm | MFCD27635184 | 388.480 | C18H28O7S | 0.000 | Cc1ccc(cc1)S(=O)(=O)OCCOCCOCCC(=O)OC(C)(C)C | 1g | 229582400
Tos-PEG3-t-butyl ester | Broadpharm | 850090-13-0 | MFCD27635184 | 388.480 | C18H28O7S | 0.000 | Cc1ccc(cc1)S(=O)(=O)OCCOCCOCCC(=O)OC(C)(C)C | 1g | 229582400
eMolecules 105589-77-3 | Tr-PEG3 | Broadpharm | MFCD17926568 | 348.442 | C23H24O3 | 95.000 | OCCOCCOC(c1ccccc1)(c1ccccc1)c1ccccc1 | 1g | 340377176
Tr-PEG3 | Broadpharm | 105589-77-3 | MFCD17926568 | 348.442 | C23H24O3 | 95.000 | OCCOCCOC(c1ccccc1)(c1ccccc1)c1ccccc1 | 1g | 340377176
eMolecules 2055023-35-1 | N-Boc-N-bis(PEG3-acid) | Broadpharm | MFCD29912757 | 525.592 | C23H43NO12 | 98.000 | CC(C)(C)OC(=O)N(CCOCCOCCOCCC(O)=O)CCOCCOCCOCCC(O)=O | 100mg | 393649478
N-Boc-N-bis(PEG3-acid) | Broadpharm | 2055023-35-1 | MFCD29912757 | 525.592 | C23H43NO12 | 98.000 | CC(C)(C)OC(=O)N(CCOCCOCCOCCC(O)=O)CCOCCOCCOCCC(O)=O | 100mg | 393649478
eMolecules 1334177-86-4 | Mal-amido-PEG8-C2-acid | Medchem Express (US) | MFCD13184956 | 592.639 | C26H44N2O13 | 98.000 | OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O | 250mg | 894458958
Mal-amido-PEG8-C2-acid | Medchem Express (US) | 1334177-86-4 | MFCD13184956 | 592.639 | C26H44N2O13 | 98.000 | OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O | 250mg | 894458958
Broadpharm Bis-PEG9-NHS ester| 100MG| CAS# 1008402-79-6
Bis-PEG9-NHS ester| 100MG| CAS# 1008402-79-6
eMolecules 2055198-05-3 | Sulfo DBCO-PEG4-amine | Broadpharm | MFCD30458045 | 674.770 | C32H42N4O10S | 90.000 | NCCOCCOCCOCCOCCC(=O)NCC(C(=O)NCCC(=O)N1Cc2ccccc2C#Cc2ccccc12)S(O)(=O)=O | 25mg | 340377134
Sulfo DBCO-PEG4-amine | Broadpharm | 2055198-05-3 | MFCD30458045 | 674.770 | C32H42N4O10S | 90.000 | NCCOCCOCCOCCOCCC(=O)NCC(C(=O)NCCC(=O)N1Cc2ccccc2C#Cc2ccccc12)S(O)(=O)=O | 25mg | 340377134